Versant Venture Capital III, L.P.
SEC-identified person · CIK 1456586 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Skye Bioscience, Inc. SKYE | Officer | filed 2023 - 2023 |
| Flexion Therapeutics Inc FLXN | Director | filed 2014 - 2016 |
| Phaserx, INC. PZRX | Officer | filed 2016 - 2016 |
| Ocular Therapeutix, INC OCUL | Officer | filed 2014 - 2015 |
| Opgen INC OPGN,OPGNW | Officer | filed 2015 - 2015 |
| Immune Design Corp. IMDZ | Officer | filed 2014 - 2014 |
| Veracyte, INC. VCYT | Officer | filed 2013 - 2013 |
| Trius Therapeutics Inc TSRX | Officer | filed 2010 - 2010 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.